浏览全部资源
扫码关注微信
抑制HBV核心启动子转录活性的化合物筛选与鉴定
Screening and identification of compounds inhibiting transcriptional activity of HBV core promoter
- 第三军医大学学报 2021年43卷第13期 页码：1192-1203
- 作者机构：
1.400016 重庆, 重庆医科大学感染性疾病分子生物学教育部重点实验室
2.400021 重庆, 重庆市中医院检验科，重庆市中医院感染性疾病中西医结合诊治实验室
- 作者简介：
[王瑜伟，E-mail: 445054416@qq.comWANG Yuwei, E-mail: 445054416@qq.com
[胡接力，E-mail: hujieli1977@163.comHU Jieli, E-mail: hujieli1977@163.com
- 基金信息：国家自然科学基金(81871635);重庆市自然科学基金面上项目(cstc2020jcyj-msxmX0764);成都中医药大学杏林学者研究基金(YYZX2019067)
DOI：10.16016/j.1000-5404.202101014
中图分类号： R373.21;R965.1;R978.7收稿：2021-01-04，
修回：2021-03-24，
纸质出版：2021-07-15
- 稿件说明：
移动端阅览
孙瑜雪, 魏霞飞, 李杰, 等. 抑制HBV核心启动子转录活性的化合物筛选与鉴定[J]. 第三军医大学学报, 2021,43(13):1192-1203.
Yuxue SUN, Xiafei WEI, Jie LI, et al. Screening and identification of compounds inhibiting transcriptional activity of HBV core promoter[J]. Journal of Third Military Medical University, 2021, 43(13): 1192-1203.
孙瑜雪, 魏霞飞, 李杰, 等. 抑制HBV核心启动子转录活性的化合物筛选与鉴定[J]. 第三军医大学学报, 2021,43(13):1192-1203. DOI： 10.16016/j.1000-5404.202101014.
Yuxue SUN, Xiafei WEI, Jie LI, et al. Screening and identification of compounds inhibiting transcriptional activity of HBV core promoter[J]. Journal of Third Military Medical University, 2021, 43(13): 1192-1203. DOI： 10.16016/j.1000-5404.202101014.
摘要
目的
2
构建靶向核心启动子转录的稳定细胞系，筛选影响乙型肝炎病毒(hepatitis B virus，HBV)转录的药物。
方法
2
利用HepG2细胞，以重组慢病毒的方式构建由HBV核心启动子驱动的Gaussia荧光素酶稳定表达细胞系(HepG2-Pcore-Gluc)。通过检测荧光素酶活性来反映核心启动子的活性变化情况。在HBV复制细胞模型中，通过Southern blot、荧光定量PCR等进一步评估经多轮筛选得到的化合物对HBV RNA、HBV DNA的影响。
结果
2
利用HepG2-Pcore-Gluc细胞模型筛选1 450种小分子化合物，第1轮筛选到41种化合物，能影响荧光素酶活性2倍以上。将这41种化合物进行第2轮剂量依赖性测试，得到2种化合物: 逆转素(Reversine)、SCH58261。进一步验证发现: Reversine在瞬时转染HBV1.3倍体的HepG2和HepG2.2.15细胞中，能够有效降低HBV RNA、HBV DNA以及HBeAg、HBsAg的水平。
结论
2
建立了一种新型、高效的抗乙肝药物筛选细胞模型(HepG2-Pcore-Gluc)，利用该模型筛选到一种新型分子Reversine，该分子可以通过抑制HBV核心启动子的转录活性来抑制HBV RNA的转录。
Abstract
Objective
2
To construct a stable cell line targeting the transcriptional activity of core promoter for screening drugs that affect the transcription of HBV.
Methods
2
HepG2-Pcore-Gluc was constructed by recombinant lentivirus to stably express Gaussia luciferase driven by HBV core promoter in HepG2 cells
and then the luciferase was detected to indicate the activity of the core promoter. Southern blotting
fluorescence quantitative PCR and other experiments were used to further evaluate the effects of the screened compounds on the levels of HBV RNA and HBV DNA after several rounds of screening in HBV-replication cell models.
Results
2
Forty-one compounds that could affect luciferase activity larger than 2 times were screened out of 1 450 compounds in the first round screening by using HepG2-Pcore-Gluc cell model
which were tested in a second round of dose-dependent test to produce 2 compounds: Reversine and SCH58261. Further
Reversine effectively decreased the levels of HBV RNA
HBV DNA
HBeAg and HBsAg in transiently-transfected HepG2 and HepG2.2.15 cells.
Conclusion
2
Reversine is identified by using a novel cell model (HepG2-Pcore-Gluc) which targets the transcription of HBV core promoter. These results provide evidences that Reversine acts through inhibiting the transcriptional activity of core promoter.
关键词
Keywords
references
ARENDS J E, LIEVELD F I, AHMAD S, et al . New viral and immunological targets for hepatitis B treatment and cure: a review[J ] . Infect Dis Ther, 2017, 6(4): 461-476. DOI:10.1007/s40121-017-0173-y.
MARTINEZ M G, VILLERET F, TESTONI B, et al . Can we cure hepatitis B virus with novel direct-acting antivirals?[J ] . Liver Int, 2020, 40(17): 27-34. DOI:10.1111/liv.14364.
TERRAULT N A, LOK A S F, MCMAHON B J, et al . Update on prevention, diagnosis, and treatment of chronic hepatitisB: AASLD 2018 hepatitis B guidance[J ] . Hepatology, 2018, 67(4): 1560-1599. DOI: 10.1002/hep.29800.
CHENG Z, ZHI X, SUN G, et al . Sodium selenite suppresses hepatitis B virus transcription and replication in human hepatoma cell lines[J ] . J Med Virol, 2016, 88(4): 653-663. DOI:10.1002/jmv.24366.
KÖSE Ș, TATLI KIȘ T, ATALAY S. Efficacy of tenofovir and entecavir in patients who relapsed after pegylated interferon therapy[J]. J Chemother, 2019, 31(4): 209-213. DOI:10.1080/1120009x.2019.1597420.
ANDERSON R T, LIM S G, MISHRA P, et al . Challenges, considerations, and principles to guide trials of combination therapies for chronic hepatitis B virus[J ] . Gastroenterology, 2019, 156(3): 529-533 e4. DOI: 10.1053/j.gastro.2018.11.062.
SUNG J J, WONG M L, BOWDEN S, et al . Intrahepatic hepatitis B virus covalently closed circular DNA can be a predictor of sustained response to therapy[J ] . Gastroenterology, 2005, 128(7): 1890-1897. DOI: 10.1053/j.gastro.2005.03.009.
WERLE-LAPOSTOLLE B, BOWDEN S, LOCARNINI S, et al . Persistence of cccDNA during the natural history of chronic hepatitis B and decline during adefovir dipivoxil therapy[J ] . Gastroenterology, 2004, 126(7): 1750-1758. DOI: 10.1053/j.gastro.2004.03.018.
WEI Z Q, ZHANG Y H, KE C Z, et al . Curcumin inhibits hepatitis B virus infection by down-regulating cccDNA-bound histone acetylation[J ] . World J Gastroenterol, 2017, 23(34): 6252-6260. DOI:10.3748/wjg.v23.i34.6252.
DENG J J, KONG K E, GAO W W, et al . Interplay between SIRT1 and hepatitis B virus X protein in the activation of viral transcription[J ] . Biochim Biophys Acta Gene Regul Mech, 2017, 1860(4): 491-501. DOI:10.1016/j.bbagrm.2017.02.007.
ZHANG Y, LOU C, XU Y, et al . Screening of inhibitors against histone demethylation jumonji domain-containing protein 3 by capillary electrophoresis[J ] . J Chromatogr A, 2020, 1613: 460625. DOI:10.1016/j.chroma.2019.460625.
NASSAL M. HBV cccDNA: viral persistence reservoir and key obstacle for a cure of chronic hepatitis B[J]. Gut, 2015, 64(12): 1972-1984. DOI:10.1136/gutjnl-2015-309809.
SANJANA N E, SHALEM O, ZHANG F. Improved vectors and genome-wide libraries for CRISPR screening[J]. Nat Methods, 2014, 11(8): 783-784. DOI:10.1038/nmeth.3047.
WEI X F, GAN C Y, CUI J, et al . Identification of compounds targeting hepatitis B virus core protein dimerization through a split luciferase complementation assay[J ] . Antimicrob Agents Chemother, 2018, 62(12). DOI: 10.1128/AAC.01302-18.
QUARLERI J. Core promoter: a critical region where the hepatitis B virus makes decisions[J]. World J Gastroenterol, 2014, 20(2): 425-435. DOI:10.3748/wjg.v20.i2.425.
KRAMVIS A, KEW M C. The core promoter of hepatitis B virus[J]. J Viral Hepat, 1999, 6(6): 415-427. DOI:10.1046/j.1365-2893.1999.00189.x.
LIU C J, KAO J H. Genetic variability of hepatitis B virus and response to antiviral therapy[J]. Antivir Ther, 2008, 13(5): 613-624.
RAMIÈRE C, SCHOLTÈS C, DIAZ O, et al . Transactivation of the h epatitis B virus core promoter by the nuclear receptor FXRalpha[J ] . J Virol, 2008, 82(21): 10832-10840. DOI:10.1128/jvi.00883-08.
TANNOUS B A, KIM D E, FERNANDEZ J L, et al . Codon-optimized Gaussia luciferase cDNA for mammalian gene expression in culture and in vivo[J ] . Mol Ther, 2005, 11(3): 435-443. DOI:10.1016/j.ymthe.2004.10.016.
BOSCO B, DEFANT A, MESSINA A, et al . Synthesis of 2, 6-diamino-substituted purine derivatives and evaluation of cell cycle arrest in breast and colorectal cancer cells[J ] . Molecules, 2018, 23(8): 1996. DOI: 10.3390/molecules23081996.
CHENG L, WANG H, GUO K C, et al . Reversine, a substituted purine, exerts an inhibitive effect on human renal carcinoma cells via induction of cell apoptosis and polyploidy[J ] . Oncotargets Ther, 2018, 11: 1025-1035. DOI:10.2147/OTT.S158198.
LU Y C, LEE Y R, LIAO J D, et al . Reversine induced multinucleated cells, cell apoptosis and autophagy in human non-small cell lung cancer cells[J ] . PLoS One, 2016, 11(7): e0158587. DOI:10.1371/journal.pone.0158587.
PICCOLI M, GHIROLDI A, MONASKY M M, et al . Reversine: a synthetic purine with a dual activity as a cell dedifferentiating agent and a selective anticancer drug[J ] . Curr Med Chem, 2020, 27(21): 3448-3462. DOI:10.2174/0929867326666190103120725.
KALKERI R, PENG J Z, HUANG C S, et al . HBV core promoter inhibition by tubulin polymerization inhibitor (SRI-32007)[J ] . Adv Virol, 2020, 2020: 8844061. DOI:10.1155/2020/8844061.
WAHLI W, MICHALIK L. PPARs at the crossroads of lipid signaling and inflammation[J]. Trends Endocrinol Metab, 2012, 23(7): 351-363. DOI: 10.1016/j.tem.2012.05.001.
TURTON K L, MEIER-STEPHENSON V, BADMALIA M D, et al . Host transcription factors in hepatitis B virus RNA synthesis[J ] . Viruses, 2020, 12(2): 160. DOI: 10.3390/v12020160.
GEHRING A J, PROTZER U. Targeting innate and adaptive immune responses to cure chronic HBV infection[J]. Gastroenterology, 2019, 156(2): 325-337. DOI:10.1053/j.gastro.2018.10.032.
0
浏览量
0
下载量
0
CSCD
- 网络PDF下载
- Meta-XML下载
- BibTeX下载
- Endnote下载
- RefMan 下载
- NoteExpress下载
- NoteFirst下载
关联资源
相关文章
相关作者
相关机构
- 技术支持由北京北大方正电子有限公司提供 京ICP备09064830号-19
京公网安备11010802024621 - 本系统建议在Chrome、 IE9+ 以上版本浏览器阅读本站内容，360浏览器请切换至极速模式
- Cookies帮助我们提供服务并提供个性化体验。使用本网站，即表示您同意我们使用Cookies
